Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.50 |
| ▸ | GAA | P10253 | 1/20 | 0.50 |
| ▸ | GFER | P55789 | 1/20 | 0.50 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.50 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.47 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.47 |
| ▸ | HPGD | P15428 | 3/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | IDO1 | P14902 | 2/20 | 0.46 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.43 |
| ▸ | RAB9A | P51151 | 2/20 | 0.43 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | PKM | P14618 | 1/20 | 0.43 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.43 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.43 |
| ▸ | RELA | Q04206 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12400239 | 0.87 | SLC7A5 (0.68) | SLC7A5ALDH1A1GAAGFERHSP90AB1 | |
| SCHEMBL6237903 | 0.84 | RAB9A (0.55) | ALDH1A1SMN1; SMN2RAB9ANPC1PKM | |
| SCHEMBL30628320 | 0.83 | L3MBTL1 (0.45) | ALDH1A1IDO1MAPK8SMN1; SMN2RAB9A | |
| SCHEMBL1273755 | 0.83 | L3MBTL1 (0.45) | ALDH1A1IDO1MAPK8SMN1; SMN2RAB9A | |
| SCHEMBL972580 | 0.83 | SIRT2 (0.51) | ALDH1A1CYP4F2CYP4A11IDO1MAPK8 | |
| SCHEMBL4394735 | 0.81 | SLC7A5 (0.62) | SLC7A5ALDH1A1GAAGFERHSP90AB1 | |
| SCHEMBL21208417 | 0.81 | MTNR1A (0.43) | SLC7A5IDO1MAPK8SMN1; SMN2RAB9A | |
| SCHEMBL2210286 | 0.80 | CYP1A2 (0.52) | ALDH1A1GAAIDO1SMN1; SMN2RAB9A | |
| SCHEMBL7173394 | 0.80 | ALDH1A1 (0.47) | ALDH1A1CYP4F2CYP4A11HPGDMAPT | |
| SCHEMBL7718934 | 0.80 | SLC7A5 (0.60) | SLC7A5ALDH1A1GAAGFERHSP90AB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 88 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4673139-A1 | NBD1 MODULATORS AND METHODS OF USING THE SAME | Sionna Therapeutics Inc. (US) | 2026-01-07 | — | — | EP | disclosed |
| US-20260001914-A1 | MACROCYCLIC PEPTIDES TARGETING KRAS | MERCK SHARP & DOHME LLC (US) | 2026-01-01 | — | — | US | disclosed |
| US-20250195699-A1 | Radiolabeled Mu Opioid Antagonist and Methods of Making and Using the Same | REGENTS OF THE UNIVERSITY OF MICHIGAN, C/O INNOVATION PARTNERSHIPS | 2025-06-19 | — | — | US | disclosed |
| EP-4558513-A1 | MACROCYCLIC PEPTIDES TARGETING KRAS | Merck Sharp & Dohme LLC (US) | 2025-05-28 | — | — | EP | disclosed |
| WO-2024182742-A1 | NBD1 MODULATORS AND METHODS OF USING THE SAME | SIONNA THERAPEUTICS INC. (US) | 2024-09-06 | — | — | WO | disclosed |
| US-20240279220-A1 | INDOLE COMPOUNDS AND METHODS OF USE | SIONNA THERAPEUTICS INC. | 2024-08-22 | — | — | US | disclosed |
| EP-4396179-A1 | INDOLE COMPOUNDS AND METHODS OF USE | GENZYME CORPORATION (US) | 2024-07-10 | — | — | EP | disclosed |
| CN-118201919-A | Indole compounds and methods of use | 健赞公司 | 2024-06-14 | — | — | CN | disclosed |
| WO-2024020159-A1 | MACROCYCLIC PEPTIDES TARGETING KRAS | MERCK SHARP & DOHME LLC (US) | 2024-01-25 | — | — | WO | disclosed |
| EP-4177248-A1 | A CLASS OF TRICYCLIC COMPOUNDS, PREPARATION METHOD THEREFOR, AND MEDICAL USE THEREOF | Hefei Institute of Pharmaceutical Industry Co., Ltd. (CN) | 2023-05-10 | — | — | EP | disclosed |
| US-7115741-B2 | 4-thieno[2,3-D]pyrimidin-4-YL piperazine compounds | ALEXION PHARMACEUTICALS, INC. | 2006-10-03 | — | — | US | disclosed |
| US-20060014790-A1 | Methods of treatment of amyloidosis using spirocyclohexane aspartyl-protease inhibitors | ELAN PHARMACEUTICALS, INC. | 2006-01-19 | — | — | US | disclosed |
| US-20050261273-A1 | Substituted urea and carbamate, phenacyl-2-hydroxy-3-diaminoalkane, and benzamide-2-hydroxy-3-diaminoalkane aspartyl-protease inhibitors | ELAN PHARMACEUTICALS, INC. | 2005-11-24 | — | — | US | disclosed |
| WO-2005087215-A1 | SUBSTITUTED UREA AND CARBAMATE, PHENACYL-2-HYDROXY-3-DIAMINOALKANE, AND BENZAMIDE-2-HYDROXY-3-DIAMINOALKANE ASPARTYL-PROTEASE INHIBITORS | ELAN PHARMACEUTICALS, INC. (US) | 2005-09-22 | — | — | WO | disclosed |
| EP-1575495-A2 | COMPOUNDS AND METHODS | SmithKline Beecham Corporation (US) | 2005-09-21 | — | — | EP | disclosed |
| WO-2005070407-A1 | METHODS OF TREATMENT OF AMYLOIDOSIS USING ASPARTYL-PROTEASE INIHIBITORS | ELAN PHARMACEUTICALS, INC. (US) | 2005-08-04 | — | — | WO | disclosed |
| US-20050113580-A1 | Amide compounds and methods of using the same | SMITHKLINE BEECHAM CORP | 2005-05-26 | — | — | US | disclosed |
| WO-2003082205-A2 | COMPOUNDS AND METHODS | SMITHKLINE BEECHAM CORPORATION (US) | 2003-10-09 | — | — | WO | disclosed |
| US-20030153556-A1 | Piperazine and homopiperazine compounds | MILLENNIUM PHARMACEUTICALS, INC. | 2003-08-14 | — | — | US | disclosed |
| WO-2003022214-A2 | PIPERAZINE AND HOMOPIPERAZINE COMPOUNDS | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2003-03-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240279220-A1 | INDOLE COMPOUNDS AND METHODS OF USE | CFTR, INMT, IDO1 | SLC7A5 208/4885ALDH1A1 784/4885GAA 1144/4885 |
| US-20050261273-A1 | Substituted urea and carbamate, phenacyl-2-hydroxy-3-diaminoalkane, and benzamide-2-hydroxy-3-diaminoalkane aspartyl-protease inhibitors | DNPEP, ASPH, PEPD | SLC7A5 2330/4885ALDH1A1 443/4885GAA 192/4885 |
| US-20030153556-A1 | Piperazine and homopiperazine compounds | HAMP, MPL, F2 | SLC7A5 3356/4885ALDH1A1 3346/4885GAA 4771/4885 |
| US-20060014790-A1 | Methods of treatment of amyloidosis using spirocyclohexane aspartyl-protease inhibitors | ASPH, DNPEP, ACE | SLC7A5 2879/4885ALDH1A1 393/4885GAA 104/4885 |
| US-20050113580-A1 | Amide compounds and methods of using the same | NR1H2, NR1H3, PPARA | SLC7A5 1328/4885ALDH1A1 1460/4885GAA 1405/4885 |
| US-20260001914-A1 | MACROCYCLIC PEPTIDES TARGETING KRAS | KRAS, NRAS, HRAS | SLC7A5 308/4885ALDH1A1 3909/4885GAA 2751/4885 |
| US-20250195699-A1 | Radiolabeled Mu Opioid Antagonist and Methods of Making and Using the Same | OPRM1, OPRK1, OPRL1 | SLC7A5 981/4885ALDH1A1 2454/4885GAA 3130/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.